Kdr - kinase insert domain receptor Gene

中文名称：激酶插入域受体

种属: Rattus norvegicus

同用名: Vegfr-2

基因 ID: 25589 | 基因类型: protein coding

关于 Kdr

Primary_assembly 14: 32,217,871-32,261,018 forward strand.mRatBN7.2:CM026987.1

This gene has 2 transcripts (splice variants), 199 orthologues, 54 paralogues and is associated with 125 phenotypes. Biased expression in Lung (RPKM 646.5), Adrenal (RPKM 253.7) and 8 other tissues.

功能概要

该基因编码的蛋白可启动生长因子结合活性和血管内皮生长因子激活受体活性。涉及多个过程，包括神经元的生成；内皮细胞增殖的正向调节；和细胞内信号转导的正调控。位于多个细胞成分中，包括神经元投射；神经细胞体；和质膜。用于研究子宫粘连；脑缺血;膀胱炎;和心肌梗塞。多种疾病的生物标志物，包括动脉疾病（多种）；阳痿;卵巢过度刺激综合征；前列腺疾病（多种）；和早产儿视网膜病变。该基因的人类直系同源物与多种疾病有关，包括动脉疾病（多种）；胃肠系统癌症（多发性）；胶质母细胞瘤;黄斑变性（多发性）；和胰腺癌（多发）。与人类 KDR（激酶插入域受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables growth factor binding activity and vascular endothelial growth factor-activated receptor activity. Involved in several processes, including generation of neurons; positive regulation of endothelial cell proliferation; and positive regulation of intracellular signal transduction. Located in several cellular components, including neuron projection; neuronal cell body; and plasma membrane. Used to study adhesions of uterus; brain ischemia; cystitis; and myocardial infarction. Biomarker of several diseases, including artery disease (multiple); impotence; ovarian hyperstimulation syndrome; prostate disease (multiple); and retinopathy of prematurity. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); gastrointestinal system Cancer (multiple); glioblastoma; macular degeneration (multiple); and pancreatic Cancer (multiple). Orthologous to human VEGFR2/KDR/Flk-1 (kinase insert domain receptor). [provided by Alliance of Genome Resources, Apr 2022]

Kdr 基因产物(1)

mRNA	Protein	Name
NM_013062.2	NP_037194.2	vascular endothelial growth factor receptor 2 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables growth factor binding	IMP IMP: 通过突变表型推断	9442048	RGD
enables growth factor binding	IPI IPI: 通过物理相互作用推断	9160888	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	10329451	RGD
enables vascular endothelial growth factor receptor activity	IMP IMP: 通过突变表型推断	9442048	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in endochondral bone growth	IMP IMP: 通过突变表型推断	14612527	RGD
involved in endothelial tube morphogenesis	IMP IMP: 通过突变表型推断	25942475	RGD
involved in male gonad development	IDA IDA: 通过直接分析推断	16672722	RGD
involved in negative regulation of neuron apoptotic process	IMP IMP: 通过突变表型推断	15780476	RGD
involved in negative regulation of systemic arterial blood pressure	IGI IGI: 通过遗传相互作用推断	12052848	RGD
involved in neuron projection morphogenesis	IMP IMP: 通过突变表型推断	16329123	RGD
involved in positive regulation of TOR signaling	IMP IMP: 通过突变表型推断	18221855	RGD
involved in positive regulation of angiogenesis	IDA IDA: 通过直接分析推断	15951738	RGD
involved in positive regulation of calcium-mediated signaling	IMP IMP: 通过突变表型推断	18221855	RGD
involved in positive regulation of cell migration	IMP IMP: 通过突变表型推断	17881084	RGD
involved in positive regulation of cell population proliferation	IMP IMP: 通过突变表型推断	17881084	RGD
involved in positive regulation of cytosolic calcium ion concentration	IMP IMP: 通过突变表型推断	18221855	RGD
involved in positive regulation of endothelial cell proliferation	IMP IMP: 通过突变表型推断	17360578	RGD
involved in positive regulation of long-term neuronal synaptic plasticity	IMP IMP: 通过突变表型推断	18221855	RGD
involved in positive regulation of neurogenesis	IEP IEP: 通过表达模式推断	15258583	RGD
involved in positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	18221855	RGD
involved in protein autophosphorylation	IDA IDA: 通过直接分析推断	9263985	RGD
involved in response to axon injury	IEP IEP: 通过表达模式推断	20187850	RGD
involved in response to hypoxia	IMP IMP: 通过突变表型推断	15780476	RGD
involved in response to oxygen levels	IEP IEP: 通过表达模式推断	15885787	RGD
involved in response to xenobiotic stimulus	IMP IMP: 通过突变表型推断	17360578	RGD
involved in vascular endothelial growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	9442048	RGD
involved in vasodilation	IGI IGI: 通过遗传相互作用推断	12052848	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in neuronal cell body	IDA IDA: 通过直接分析推断	11934468	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Kdr 蛋白结构

Ig_3

I-set

VEGFR-2_TMD

PTKc_VEGFR2

0
300
600
900
1200
1343 a.a.

蛋白主名

其他名称

vascular endothelial growth factor receptor 2

FLK-1	FLK1 kinase insert domain receptor (VEGF receptor 2)
FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2)	fetal liver kinase 1
kinase insert domain protein receptor	protein-tyrosine kinase receptor flk-1

重组 Kdr 蛋白

目录号	产品名	蛋白编号	纯度
HY-P73481	VEGFR-2 Protein, Rat (HEK293, Fc)	AAH87029.1 (M1-E760)	≥95%
HY-P74470	VEGFR-2 Protein, Rat (HEK293, His)	AAH87029 (A20-E760)	≥95%

相关产品

Approval

生物活性分子 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-16749	Pexidartinib		99.64%	是
HY-10260	Vandetanib		99.95%	是
HY-112306	Ripretinib		98.90%	是
HY-16749A	Pexidartinib hydrochloride		99.86%	是
HY-14914	Azilsartan		99.51%	否
HY-10330	Toceranib	Inhibitor	96.86%	否
HY-10330A	Toceranib phosphate	Inhibitor	98.54%	否
HY-10260B	Vandetanib hydrochloride		/	否
HY-10260A	Vandetanib trifluoroacetate		/	否

Clinical Phase

生物活性分子 (15)

目录号	产品名	作用方式	纯度	Phase
HY-50751	Linifanib		99.28%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-12018	Vatalanib dihydrochloride		99.91%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-10203	Vatalanib	Inhibitor	99.93%	Phase 3
HY-12018A	Vatalanib hydrochloride	Inhibitor	/	Phase 3
HY-50751G	Linifanib (GMP)	Inhibitor	/	Phase 3
HY-110272	Vatalanib succinate	Inhibitor	/	Phase 3
HY-10374	Semaxinib	Inhibitor	99.96%	Phase 2
HY-13024	Rebastinib		99.91%	Phase 2
HY-10338	Foretinib	Inhibitor	99.06%	Phase 2
HY-10987A	ENMD-2076		99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.42%	Phase 2
HY-10204	OSI-930		98.57%	Phase 1
HY-100315	XL 999	Inhibitor	99.34%	Phase 1

抗体抑制剂 (2)

目录号	产品名	作用方式	纯度	Phase
HY-P99830	Conbercept		98.42%	Phase 4
HY-P99768	Olinvacimab	Inhibitor	95.00%	Phase 2

Pre-clinical Phase

生物活性分子 (39)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12299	WH-4-023	Inhibitor	99.75%	否
HY-151361	AMPK-IN-3	Inhibitor	98.51%	否
HY-W062835	CGP77675	Inhibitor	99.00%	否
HY-13561	AZM475271	Inhibitor	99.85%	否
HY-13838	PLX647	Inhibitor	99.79%	否
HY-133551	WF-47-JS03	Inhibitor	99.63%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-132135	(1E)-CFI-400437 dihydrochloride	Inhibitor	98.08%	否
HY-18302	c-Kit-IN-5-1	Inhibitor	98.16%	否
HY-P1663	ATWLPPR Peptide	Inhibitor	99.21%	否
HY-15769	WHI-P180	Inhibitor	99.62%	否
HY-10517A	(Z)-Orantinib	Inhibitor	99.44%	否
HY-125741	GW768505A free base	Inhibitor	98.66%	否
HY-13785	ZM 306416	Inhibitor	99.80%	否
HY-119757	Tyrphostin AG1433	Inhibitor	99.08%	否
HY-15814	HG-7-85-01		99.94%	否
HY-118105	RK-20448	Inhibitor	99.38%	否
HY-100824	PP2 Analog	Inhibitor	/	否
HY-10260S	Vandetanib-d6		/	否
HY-10260S1	Vandetanib-d4		/	否
HY-10260S2	Vandetanib-13C6		/	否
HY-120214	TAS05567	Inhibitor	/	否
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	否
HY-14979	ML786	Inhibitor	/	否
HY-14979A	ML786 dihydrochloride	Inhibitor	/	否
HY-15334	CEP-5214	Inhibitor	/	否
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	否
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	否
HY-18318	Takeda-6D	Inhibitor	/	否
HY-RS07226	KDR Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07227	Kdr Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07228	Kdr Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W062835A	CGP77675 hydrate	Inhibitor	/	否
HY-10330S	Toceranib-d8	Inhibitor	/	否
HY-110045	ZM-306416 hydrochloride	Inhibitor	/	否
HY-119757A	Tyrphostin AG1433 hydrochloride	Inhibitor	/	否
HY-149451	SYHA1815	Inhibitor	/	否
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	否
HY-101628	VEGFR-2-IN-9	Inhibitor	/	否

抗体抑制剂 (3)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P990318	Alacizumab	Inhibitor	/	否
HY-P990542	Anti-VEGFR2/KDR/CD309 Antibody	Inhibitor	/	否
HY-P990543	Anti-VEGFR2/KDR/CD309 Antibody (AT001)	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Kdr	NCBI	NCBI:3791
Macaca fascicularis	Kdr	NCBI	NCBI:102136227
Macaca mulatta	Kdr	NCBI	NCBI:698293

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4